Clinical Trials Logo

Clinical Trial Summary

This study is a 12 week prospective, comparative investigation in subjects diagnosed with uncontrolled genetic generalised epilepsy (GGE) also known as idiopathic generalised epilepsy (IGE). The purpose of the study is to evaluate whether the 24/7 EEG™ SubQ system, a subcutaneous implantable device, will demonstrate seizure sensitivity approximating that of inpatient video-EEG monitoring with the standard 10-20 electrode system.


Clinical Trial Description

The purpose of this study is to evaluate the performance of the '24/7 EEG SubQ system' monitoring device in uncontrolled generalised genetic epilepsy syndromes. It is hypothesised that this system will demonstrate seizure sensitivity comparable to Video EEG monitoring with a standard 10-20 electrode system, which is done in a hospital setting and is considered the gold standard for a diagnosis/evaluation of epilepsy. Ten patients will be recruited with uncontrolled genetic generalised epilepsy. All adults between ages 18-75 years with the ability to give full informed consent. This is an subcutaneously implanted ambulatory device; we will record EEG over a period of twelve weeks. The device consists of two parts: an implant - UNEEG - and an external storage unit (ELG) x 2 that also powers up the implant wirelessly through an inductive link. When the two parts are aligned on opposite sides of the skin: an external pad sits over the implanted device and EEG is recorded from the implanted contacts. The device is inserted under local anaesthetic by a neurosurgeon subcutaneously overlying the temporal region. Seizures will be recorded for 12 weeks, then the device will be removed. During the recording period, the patient will undertake video EEG monitoring with the aim of diagnosing seizures by video EEG (gold standard for diagnosis) and comparing the video EEG data with the UNEEG-recorded data. Throughout the recording period the patients will be overseen by their neurology team. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05241678
Study type Observational [Patient Registry]
Source Royal College of Surgeons, Ireland
Contact
Status Completed
Phase
Start date February 15, 2022
Completion date December 29, 2023

See also
  Status Clinical Trial Phase
Completed NCT04248920 - Clinic to Community© Program for Adults With Epilepsy Admitted to Emergency Departments N/A
Completed NCT00162981 - Clobazam in Subjects With Lennox-Gastaut Syndrome Phase 2
Completed NCT00236886 - Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients Phase 3
Recruiting NCT05477121 - Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices
Recruiting NCT04959019 - Exercise for Memory Rehabilitation in Epilepsy N/A
Completed NCT00231556 - A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy Phase 3
Completed NCT04439656 - Detecting Absence Seizures Using Eye Tracking
Completed NCT00319501 - Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures. Phase 3
Completed NCT00266604 - A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy Phase 4
Completed NCT00518713 - Clobazam in Patients With Lennox-Gastaut Syndrome Phase 3
Recruiting NCT06399952 - Baker Gordon Syndrome Natural History Study
Completed NCT05297695 - Helicobacter Pylori Eradication Therapy for Epileptic Children Phase 2/Phase 3